Predictors of nonsentinel lymph node positivity in patients with a positive sentinel node for melanoma

被引:107
作者
Sabel, MS
Griffith, K
Sondak, VK
Lowe, L
Schwartz, JL
Cimmino, VM
Chang, AE
Rees, RS
Bradford, CR
Johnson, TM
机构
[1] Univ Michigan, Hlth Syst, Dept Surg, Ann Arbor, MI 48109 USA
[2] Univ Michigan, Hlth Syst, Dept Pathol, Ann Arbor, MI 48109 USA
[3] Univ Michigan, Hlth Syst, Dept Dermatol, Ann Arbor, MI 48109 USA
[4] Univ Michigan, Hlth Syst, Dept Otolaryngol, Ann Arbor, MI 48109 USA
[5] Univ Michigan, Biostat Core, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA
关键词
D O I
10.1016/j.jamcollsurg.2005.03.029
中图分类号
R61 [外科手术学];
学科分类号
摘要
BACKGROUND: Patients found to harbor melanoma micrometastases in the sentinel lymph node (SLN) are recommended to proceed to complete lymph node dissection (CLND), although the majority of patients will have no additional disease identified in the nonsentinel lymph nodes (NSLNs). We sought to assess predictive factors associated with finding positive NSLNs, and identify a subset of patients with low likelihood of finding additional disease on CLND. STUDY DESIGN: We queried our prospective melanoma database for patients from January 1996 to August 2003 with a positive SLN. Univariable logistic regression models were fit for multiple factors and a positive NSLN. To derive a probabilistic model for occurrence of one or more positive NSLN(s), a multivariable logistic model was fit using a stepwise variable selection method. RESULTS: Of 980 patients who underwent SLN biopsy for cutaneous melanoma, 232 (24%) had a positive SLN; 221 (23%) followed by CLND. Of these patients, 34 (15%) had one or more positive NSLN(s). In multivariable analysis, male gender (odds ratio [OR] 3.6 [95% Cl 1.33, 9.711; P = 0.01), Breslow thickness (OR4.58 [95% Cl 1.28,16.36]; p = 0.019), extranodal extension (OR3.2 [95% Cl 1.0, 10.5]; p = 0.05), and three or more positive sentinel nodes (OR 65.81 [95% Cl 5.2, 825.7]; p = 0.001) were all associated with the likelihood of finding additional positive nodes on CLND. Of 47 patients with minimal tumor burden in the SLN, only 1(2%) had additional disease in the NSLN. CONCLUSIONS: These results provide additional data to plan clinical trials to answer the question of who can safely avoid CLND after a positive SLN. Patients with minimal tumor burden in the SLN might be the most likely group, although defining "minimal tumor burden" must be standardized. Serial sectioning and immunohistochemistry on the NSLN in any "low-risk" group must be performed in a clinical trial to confirm that residual disease is unlikely before avoiding CLND can be recommended. (c) 2005 by the American College of Surgeons.
引用
收藏
页码:37 / 47
页数:11
相关论文
共 30 条
[1]   Tumor mitotic rate is a more powerful prognostic indicator than ulceration in patients with primary cutaneous melanoma - An analysis of 3661 patients from a single center [J].
Azzola, MF ;
Shaw, HM ;
Thompson, JF ;
Soong, SJ ;
Scolyer, RA ;
Watson, GF ;
Colman, MH ;
Zhang, YT .
CANCER, 2003, 97 (06) :1488-1498
[2]   Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0 to 4.0 mm) [J].
Balch, CM ;
Soong, SJ ;
Ross, MI ;
Urist, MM ;
Karakousis, CP ;
Temple, WJ ;
Mihm, MC ;
Barnhill, RL ;
Jewell, WR ;
Wanebo, HJ ;
Harrison, R .
ANNALS OF SURGICAL ONCOLOGY, 2000, 7 (02) :87-97
[3]   Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger [J].
Balch, CM ;
Soong, SJ ;
Bartolucci, AA ;
Urist, MM ;
Karakousis, CP ;
Smith, TJ ;
Temple, WJ ;
Ross, MI ;
Jewell, WR ;
Mihm, MC ;
Barnhill, RL ;
Wanebo, HJ .
ANNALS OF SURGERY, 1996, 224 (03) :255-263
[4]   Prognostic significance of occult metastases detected by sentinel lymphadenectomy and reverse transcriptase-polymerase chain reaction in early-stage melanoma patients [J].
Bostick, PJ ;
Morton, DL ;
Turner, RR ;
Huynh, KT ;
Wang, HJ ;
Elashoff, R ;
Essner, R ;
Hoon, DSB .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (10) :3238-3244
[5]   Sentinel lymph node biopsy in cutaneous melanoma: The WHO Melanoma Program experience [J].
Cascinelli, N ;
Belli, F ;
Santinami, M ;
Fait, V ;
Testori, A ;
Ruka, W ;
Cavaliere, R ;
Mozzillo, N ;
Rossi, CR ;
MacKie, RM ;
Nieweg, O ;
Pace, M ;
Kirov, K .
ANNALS OF SURGICAL ONCOLOGY, 2000, 7 (06) :469-474
[6]   Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomised trial [J].
Cascinelli, N ;
Morabito, A ;
Santinami, M ;
MacKie, RM ;
Belli, F .
LANCET, 1998, 351 (9105) :793-796
[7]   Sentinel lymph node micrometastasis and other histologic factors that predict outcome in patients with thicker melanomas [J].
Cherpelis, BS ;
Haddad, F ;
Messina, J ;
Cantor, AB ;
Fitzmorris, K ;
Reintgen, DS ;
Fenske, NA ;
Glass, LF .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2001, 44 (05) :762-766
[8]   Sentinel lymph node biopsy in the management of patients with primary cutaneous melanoma: Review of a large single-institutional experience with an emphasis on recurrence [J].
Clary, BM ;
Brady, MS ;
Lewis, JJ ;
Coit, DG .
ANNALS OF SURGERY, 2001, 233 (02) :250-258
[9]   OCCULT MELANOMA IN LYMPH-NODES DETECTED BY ANTISERUM TO S-100 PROTEIN [J].
COCHRAN, AJ ;
WEN, DR ;
HERSCHMAN, HR .
INTERNATIONAL JOURNAL OF CANCER, 1984, 34 (02) :159-163
[10]   Prediction of metastatic melanoma in nonsentinel nodes and clinical outcome based on the primary melanoma and the sentinel node [J].
Cochran, AJ ;
Wen, DR ;
Huang, RR ;
Wang, HJ ;
Elashoff, R ;
Morton, DL .
MODERN PATHOLOGY, 2004, 17 (07) :747-755